TRDA
$12.59
Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible.
Recent News
Arcutis Biotherapeutics, Inc. (ARQT) Surpasses Q4 Earnings and Revenue Estimates
Arcutis Biotherapeutics (ARQT) delivered earnings and revenue surprises of +290.39% and +11.93%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Repligen (RGEN) Tops Q4 Earnings and Revenue Estimates
Repligen (RGEN) delivered earnings and revenue surprises of +11.26% and +2.96%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Entrada Therapeutics, Inc. (TRDA) Q4 Earnings Expected to Decline
Entrada Therapeutics (TRDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
EyePoint (EYPT) Surges 15.2%: Is This an Indication of Further Gains?
EyePoint (EYPT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Entrada Therapeutics Teases Data-Rich 2026 With DMD and DM1 Catalysts at Guggenheim Summit
Entrada Therapeutics (NASDAQ:TRDA) used a presentation at Guggenheim’s 2026 Emerging Outlook Biotech Summit to outline its pipeline focus on intracellular therapeutics and to preview multiple clinical data catalysts expected in 2026, particularly in Duchenne muscular dystrophy (DMD) and myotonic dys